MedTrace Logo

Dose, Safety and Pathogenicity of SARS-CoV-2 (COVID-19) Omicron Virus (BA.5)

NCT06492564 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2025-11-21

No results posted yet for this study

Summary

An Exploratory Study to Establish the Dose, Safety and Pathogenicity of a SARS-CoV-2 Omicron Challenge Strain (BA.5) in Healthy Participants 18 to 40 Years of Age

Conditions

Interventions

BIOLOGICAL

SARS-CoV-2 omicron virus dose arm 1

Low dose, approximately 10\^4 TCID50/mL

BIOLOGICAL

SARS-CoV-2 omicron virus dose arm 2

Medium dose, approximately 10\^5 TCID50/mL

BIOLOGICAL

SARS-CoV-2 omicron virus dose arm 3

High dose, approximately 10\^6 TCID50/mL

Sponsors & Collaborators

  • Hvivo

    lead INDUSTRY

Principal Investigators

  • Melissa Bevan, MBBS · hVIVO Services Ltd.

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-12-02
Primary Completion
2025-10-16
Completion
2025-10-16

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06492564 on ClinicalTrials.gov